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ABSTRACT
Background & Aims: Carriage of rs738409:G in patatin-like phospholipase domain-containing 3 (PNPLA3) 
is associated with an increased risk for developing alcohol-related cirrhosis and hepatocellular carcinoma 
(HCC).  Recently, rs72613567:TA in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) was shown to 
be associated with a reduced risk for developing alcohol-related liver disease and to attenuate the risk 
associated with PNPLA3 rs738409:G.  This study explores the risk-associations between these two genetic 
variants and the development of alcohol-related cirrhosis and HCC. 
Approach and Results: Variants in HSD17B13 and PNPLA3 were genotyped in 6,171 participants, 
including: 1,031 with alcohol-related cirrhosis and HCC; 1,653 with alcohol-related cirrhosis without HCC; 
2,588 alcohol misusers with no liver disease; and 899 healthy controls.  Genetic associations with the risks 
for alcohol-related cirrhosis and HCC were determined using logistic regression analysis. Carriage of 
HSD17B13 rs72613567:TA was associated with a lower risk for both cirrhosis (OR 0.79 [95% CI 0.72-0.88], 
p=8.13×10-6) and HCC (OR 0.77 [95% CI 0.68-0.89], p=2.27×10-4), while carriage of PNPLA3 rs738409:G was 
associated with an increased risk for developing cirrhosis (OR 1.70 [95% CI 1.54-1.88], p=1.52x10-26) and 
HCC (OR 1.77 [95% CI 1.58-1.98], p=2.31×10-23).  These associations remained significant after adjusting 
for age, sex, body mass index, type II diabetes mellitus and country.  Carriage of HSD17B13 rs72613567:TA 
attenuated the risk for developing cirrhosis associated with PNPLA3 rs738409:G in both men and women 
but the protective effect against the subsequent development of HCC was only observed in men 
(p=1.72×10−4; ORallelic, 0.75; 95% CI, 0.64–0.87).
Conclusions: Carriage of variants in PNPLA3 and HSD17B13 differentially affect the risk for developing 
advanced alcohol-related liver disease.  A genotypic/phenotypic risk score might facilitate earlier 
diagnosis of HCC in this population.
Word count: 273
INTRODUCTION
Alcohol-related liver disease has a global prevalence of 12% and accounts for half of all cirrhosis-
associated deaths in Europe and the United States.1-3 Alcohol-related cirrhosis is now the second 
most common indication for liver transplantation, accounting for approximately 40% of all 
primary liver transplants in Europe and approximately 25% in the United States.4  A
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Chronic alcohol misuse is associated with the development of a broad spectrum of liver injury.  
Hepatic steatosis develops in most heavy alcohol users, but more substantial liver injury only 
develops with persistent alcohol misuse over time; inflammation and progressive fibrosis will 
develop in 10 to 35% of individuals, whereas cirrhosis is observed in only 10 to 15%.5-7  Between 
5 to 15% of people with alcohol-related cirrhosis are at risk for developing hepatocellular 
carcinoma (HCC); the annual incidence is 2.5 to 3.0%, with a 5-year cumulative risk of around 
8%.8-11  The global incidence of HCC is increasing; it is now the fifth most frequent cancer and 
third most frequent cause of cancer-related mortality world-wide; one third of cases develop on 
a background of alcohol-related cirrhosis.12
The susceptibility to develop significant alcohol-related liver disease is determined by the 
interplay of a number of risk factors, including sex, ethnicity, the amount/pattern of alcohol 
drinking, coffee consumption, cigarette smoking, co-morbidies such as obesity, type 2 diabetes 
and hepatitis C infection and a number of host genetic factors.13  Carriage of the common 
missense variant rs738409:G in patatin-like phospholipase domain-containing 3 (PNPLA3) is the 
most robustly validated risk locus for the development of alcohol-related cirrhosis and HCC,14-19 
accounting for 26.6%14 and 43.5%18 of the variance, respectively. Two further gene variants, 
rs58542926 in transmembrane 6 superfamily member 2 (TM6SF2) and rs641738 in membrane 
bound O-acetyltransferase domain containing 7 (MBOAT7), are additional risk factors, albeit with 
much lower effect sizes.19
Recently, Abul-Husn and colleagues20 identified a splice variant rs72613567 in hydroxysteroid 17-
beta dehydrogenase 13 (HSD17B13), which appeared to protect against the development of 
chronic liver injury in people of European ancestry.  HSD17B13 encodes a hepatic lipid droplet 
protein; the insertion of an adenine adjacent to the donor splice site on exon 6 (rs72613567:TA 
allele) results in an unstable and truncated protein with reduced enzymatic activity, suggesting 
that it is a loss-of-function variant.20  Abul-Husn et al.20 found that carriage of HSD17B13 
rs72613567:TA was associated with reduced serum aminotransferase activities, a reduced risk 
for developing alcohol-related and non-alcoholic fatty liver disease (NAFLD), and, more 
specifically, for developing both alcohol-related and NAFLD-related cirrhosis.20  The association 
with alcohol-related cirrhosis was the most compelling but the total number of cases was very A
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small.  This group also showed that carriage of this variant attenuated the risk of developing 
progressive liver injury derived from rs738409:G in PNPLA3. 20 
Yang et al.21 recently confirmed the association between rs72613567:TA in HSD17B13 and a 
reduction in the risk for developing alcohol-, NAFLD- and hepatitis C-related liver disease, and 
more specifically the risk of developing cirrhosis.  They also found that carriage of this variant 
protected against the development of HCC, but only in patients with a background of alcohol-
related liver disease.  The sample size was small and those with HCC were more frequently male 
and older than their counterparts without HCC.  Thus, in order to validate these findings much 
larger cohorts are needed to allow adjustments for potential confounders.21 Interactions 
between variants in HSD17B13 and PNPLA3 were not addressed in this study.
The aims of the present study were to determine whether: (i) carriage of rs72613567:TA in 
HSD17B13 protects against the development of alcohol-related cirrhosis and alcohol–related 
HCC; and (ii) to explore possible risk interactions between rs72613567:TA in HSD17B13 and 
rs738409:G in PNPLA3.
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METHODS
Study cohorts
The study population comprised of 6,171 participants drawn from one of four study cohorts:
1. Alcohol-related cirrhosis and HCC (HCC) (n=1,031)
2. Alcohol-related cirrhosis without HCC (CIRR) (n=1,653)
3. Alcohol misusers with no evident liver disease (ALC) (n=2,588)
4. Healthy controls with no history of alcohol misuse or liver disease (n = 899)
Participants in cohorts 1-3 were recruited from Hepatology units and Addiction centres across 
Europe and were of self-reported Swiss/German/Austrian/Italian/British ancestry.  Ninety of the 
UK samples with cirrhosis and HCC were obtained from the Nottingham Digestive Diseases 
Centre Biomedical Research Unit Research Tissue Bank (Rec Ref: 14/WA/1234).  Participants in 
cohort 4 were recruited from the United Kingdom.
The diagnosis of alcohol-related cirrhosis was established, as described, in detail, previously;19 
briefly, the diagnosis was based on a history of prolonged, sustained alcohol intake of a minimum 
of 40g/day in women and 60g/day in men together with histological examination of liver tissue; 
or compatible historical, clinical, laboratory, radiological and endoscopic features of advanced 
chronic liver disease. Patients were excluded if they had any other potential cause of liver injury, 
specifically if they were positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C 
immunoglobulin G (anti-HCV IgG), anti-nuclear antibodies (ANA) (titre >1:80) or anti-
mitochondrial antibodies (titre >1:40).  Patients with elevated serum ferritin levels and a 
transferrin saturation of >50%, a serum caeruloplasmin of <20mg/dl (0.2 g/dl) or a serum alpha-1 
antitrypsin of <70 mg/dL (13µmol/L) were further investigated and excluded, as appropriate. 
The diagnosis of HCC was based on histological examination of tumour tissue or evidence on 
imaging, preferably using two modalities, of lesions that were hypervascular in the arterial phase 
with washout in the portal venous or delayed phases.22 The severity of the underlying cirrhosis 
was assessed using Pugh’s modification of the Child’s grading system.23
The patients with alcohol misuse but no evidence of significant liver injury were recruited as 
described, in detail, previously;19 in brief, they had a background of alcohol consumption of at A
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least 60 g/d for women and 80 g/d for men for ≥10 years with or without features of alcohol 
dependence.24  None had historical, clinical or laboratory evidence of liver disease and its 
absence was confirmed either by a liver stiffness measurement (Fibroscan, Echosens, Paris) of 
below 6 kPa (IQR<20%) or by the absence of histological liver damage.
Healthy controls were recruited from London branches of the National Health Service blood 
transfusion service, from General Practitioners' surgeries, from amongst university students, and 
from the general public.  None currently drank alcohol above a weekly maximum of 112 g for 
women and 168 g for men, nor had they done so at any time in the past.  None had a history or 
clinical evidence of liver disease
DNA preparation and genotyping
Genomic DNA was extracted from venous blood samples and quantified using standard 
procedures.19 Genotyping of PNPLA3 rs738409 (Assay ID: C_7241_10) and HSD17B13 rs72613567 
(primer and probe sets manufactured through custom TaqMan® Assay design) was performed 
using TaqMan® SNP Genotyping Assays and Chemistries (Applied Biosystems, Waltham, MA, 
USA) on an automated platform with TECAN Freedom EVO and 384well TEMO liquid handling 
robots (TECAN, Männedorf, Switzerland) as described previously.18,19
All process data were logged and administered with a database-driven LIMS.  Reactions were 
completed and read in a 7900 HT TaqMan sequence detector system (Applied Biosystems, 
Waltham, MA, USA).  The amplification reaction was carried out with the TaqMan universal 
master mix at cycling conditions of 1 cycle for 10 minutes at 95°C, followed by 45 cycles for 15 
seconds at 95°C, and 1 minute at 60°C.
Statistical analysis
Logistic regression and SNP*SNP interaction analyses were performed using SPSS v.25.0 (IBM 
Corp., Armonk, NY, USA).  A three-way case control design was adopted: HCC vs. CIRR; CIRR vs. 
ALC; HCC vs. ALC. Genotypic and allelic tests of association were assessed using two logistic 
regression models:
Model A: univariate logistic regression;A
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Model B: adjustments for age, sex, body mass index (BMI), type 2 diabetes mellitus (T2DM) and 
country.  
Results, expressed as odds ratios (OR) with their 95% confidence intervals (CI), were derived from 
beta coefficients and their standard deviations.  Nominal two-sided asymptotic p-values are 
reported for all tests.  
The interactions between HSD17B13 and PNPLA3 were examined by logistic regression for the 
univariate additive and genotypic regression models including both main SNP effects and the 
SNP*SNP interaction term. 
Fixed-effect model meta-analysis using the inverse variance-weighted method to summarize 
effect sizes and forest plots were performed using the R package ‘metafor’ v.2.0-0.
Sex-specific post-hoc analyses for the risk associations with HSD17B13 and PNPLA3 were 
performed. The Mantel-Haenszel test for trend was applied for testing a linear trend in observed 
genotype proportions from contingency tables for (ALC < CIRR < HCC), by sex. 
The population-attributable fraction (PAF) provides an epidemiological estimate of the 
proportion of the disorder that is attributable to a given risk factor.  Thus, in this instance it is an 
estimate of how much lower the frequency of HCC would be in patients with alcohol-related 
cirrhosis, if the risk genotype(s) were eliminated from the population.
The PAF was estimated for heterozygous and homozygous carriage using the formula:25 
(x - 1)/x
where x = (1- p)2 + 2p(1- p)OR1 + p2OR2 (19); p is the allele frequency in the CIRR or ALC cohorts, 
and OR1 and OR2 are the ORs associated with hetero- and homozygosity.
Combined PAF estimates were calculated as PAF=1−(1−PAF1) (1−PAF2) (1−PAFn) based on the 
individual PAFs for each associated SNP, assuming no multiplicative interaction between them.
Ethics
The study protocol was approved by the ethics committees of the participating institutions; all 
included subjects provided written informed consent prior to inclusion into the study. A
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RESULTS
The patient cohorts were predominantly male and middle aged.  The patients with cirrhosis were 
generally older than those misusing alcohol and more likely to be overweight and diabetic.  The 
patients with cirrhosis and HCC were generally older than the patients with cirrhosis without 
malignant transformation and were proportionately more likely again to be male, overweight, 
and diabetic (Table 1).  Laboratory variables showed the expected gradients (Supplementary 
Table 1).
Genotyping was completed for both SNPs with call rates greater than 95% (Supplementary Table 
2).  All markers followed Hardy-Weinberg equilibrium (cutoff HWE P > 0.05).26  In the healthy 
controls the minor allele frequencies (MAFs) for both HSD17B13 rs72613567:TA (0.276) and 
PNPLA3 rs738409 G (0.224) were comparable to those in public databases27 and previous 
publications18-20 and did not differ significantly from the MAFs in the ALC group (Supplementary 
Table 2).  
A progressive reduction in MAFs for HSD17B13 rs72613567:TA was observed between the three 
groups: ALC (26.4%); CIRR (22.0%) and HCC (17.7%) (Ptrend= 1.09×10-15) (Supplementary Table 2). 
This contrasted with the expected stepwise increase in the MAFs for PNPLA3 rs738409:G in the 
same three groups viz. ALC (23.9%) CIRR (35.4%), HCC (49.8%) (Supplementary Table 2). 
In the univariate model, allelic and genotypic associations for HSD17B13 rs72613567:TA were 
highly significant for the comparisons HCC vs. CIRR (Pallelic = 2.27×10-4, Pgenotypic= 1.05×10-3), CIRR 
vs. ALC (Pallelic = 8.13×10-6, Pgenotypic = 1.54×10-6), and HCC vs ALC (Pallelic =1.69×10-14, Pgenotypic= 
3.22×10-14) (Table 2).  The protective effect associated with carriage of HSD17B13 rs72613567:TA 
remained significant in the CIRR and HCC cohorts after correction for sex, age, BMI, T2DM and 
country (Table 2).  The protective effect for HCC was greater with homozygous than 
heterozygous carriage of the HSD17B13 rs72613567:TA allele (Figure 1A+B).
Allelic and genotypic associations for PNPLA3 rs738409:G allele were also significantly associated 
in the CIRR (ORallelic 1.70 [1.54-1.88], Pallelic = 1.52×10-26) and HCC (ORallelic 1.77 [1.58-1.98], Pallelic = 
2.31×10-23) cohorts (Table 3). These associations were robust to corrections for sex, age, BMI, 
DMT2 and country.A
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Since patients were recruited from across Europe a meta-analysis of the HSD17B13 and PNPLA3 
loci for association with cirrhosis and HCC was performed, by country (Supplementary Tables 
3+4).  Associations were calculated consensually, but were not necessarily significant in each 
single European cohort.  However, fixed effect meta-analysis on aggregate confirmed both the 
protective and risk-enhancing effects of HSD17B13 and PNPLA3 loci, respectively, in the total 
cohort.  There was no evidence of heterogeneity (Supplementary Figures 1A-C and 2 A-C). 
The PAF for PNPLA3 rs738409 for CIRR was 27.2% (20.7% to 33.6%) and for HSD17B13 
rs72613567 -14.7% (-21.2% to -7.9%).  The combined PAF for CIRR was 16.5 %.  The PAF% for 
PNPLA3 rs738409 in HCC was 38.7% (29.3% to 47.2%) and for HSD17B13 rs72613567 -10.0%   (-
16.7% to -2.7%).  The combined PAF for HCC was 32.6%.  
The potential modifying effect of HSD17B13 rs72613567 on PNPLA3 rs738409 was explored  by 
calculating the proportion of the HCC, CIRR and ALC cohorts with different ’gene signatures‘ 
combining either PNPLA3 rs739409:G (high risk variant) with wild type HSD17B13 rs72613567:T 
(lack of protection), or the PNPLA3 rs739409 C (low risk variant) with HSD17B13 rs72613567:TA 
(protection).  A preponderance of patients in the CIRR and HCC cohorts were homozygous for 
PNPLA3 rs739409 G and for HSD17B13 rs72613567:T which is in line with the estimated risk 
contributions of each variant (Figure 2A & B).
Possible SNP*SNP interactions between HSD17B13 rs72613567 and PNPLA3 rs739409 were 
explored by testing interaction terms in the logistic regression models for the risk for developing 
CIRR and the further risk for developing HCC.  The genotypic interactions for the risk association 
with CIRR was not significant in the total study population (p = 0.598) (Supplementary Table 5) 
nor in the men only cohort (p = 0.689) (Supplementary Table 6).  None of the HSD17B13 by 
PNPLA3 genotype interaction pair combinations was significant.  The interactions in the additive 
CIRR and HCC risk models were not significant either. Thus, there does not appear to be an 
HSD17B13 rs72613567:TA × PNPLA3 rs739409:G interaction. 
In a sex-specific post hoc analysis of the HSD17B13 locus, an association with HCC disease risk 
was observed in men (P = 1.72×10−4; ORallelic, 0.75; 95% CI, 0.64–0.87) but not in women (p = 
0.772; ORallelic, 1.07; 95% CI, 0.73–1.58), while the protective effect for cirrhosis risk associated 
with carriage of HSD17B13 rs72613567:TA was observed in both sexes (Supplementary Table 7; A
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Figures 3A-C).  The association between carriage of PNPLA3 rs739409:G and cirrhosis and HCC 
disease risk showed no sex differential (Supplementary Table 8).
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DISCUSSION
The genetic contribution to the development of significant alcohol-related liver injury is gradually 
being unraveled.  Three genetic loci have been identified which are associated with an increased 
risk for developing cirrhosis at genome-wide significance, namely PNPLA3, TM6SF2, MBOAT7,19 
and at least two variants, PNPLA3 rs738409. and TM6SF2 rs58542926 , are associated with an 
increased risk for developing HCC on this background.15,16,18 
There is little published evidence for genetic variants conferring protection against the 
development of significant alcohol-related liver injury.  Indirect protection is afforded in 
individuals, primarily of East Asian ancestry, who carry rs1229984 in alcohol dehydrogenase IB 
(ADH1B)28 and/or rs671 in aldehyde dehydrogenase 2 (ALDH2)29 and, as a consequence, develop 
an abreaction to alcohol and so tend to avoid it.  
Recently, however, Abul-Husn and colleagues20 identified a splice variant, rs72613567, in 
HSD17B13, which appeared to protect against the development of chronic liver injury in people 
of European ancestry.  Specifically, this SNP appeared to confer protection against the 
development of alcohol-related and NAFLD-related cirrhosis.20 The association with alcohol-
related cirrhosis was more compelling even though the total number of cases was very small, 
amounting to only 124 in their discovery cohort and 215 in their validation cohort.  
Yang and coworkers,21 in a recent French/Belgian collaboration confirmed that rs72613567 in 
HSD17B13 confers protection against the development of alcohol-, NAFLD- and HCV-related liver 
disease.  They further showed that this SNP confers protection against the development of HCC 
but only when arising on a background of alcohol-related liver disease.  The data were adjusted 
for age, sex and the degree of hepatic fibrosis but not for other important confounders such as 
BMI, diabetes and PNPLA3 genotype.  Only half the patients with alcohol-related HCC, in this 
study, had cirrhosis.  Thus the numbers of patients with alcohol-related cirrhosis (n=1243) and 
alcohol-related HCC (n=217) were relatively small and those with HCC were more frequently 
male and older than those with cirrhosis per se.  Adjustments were not made for these possible 
confounders leading the authors to conclude that larger cohorts were needed to validate their 
findings.A
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The cohorts included in the present study were large, comprising of 1,031 patients of European 
ancestry with alcohol-related cirrhosis and HCC, and 1,653 with alcohol-related cirrhosis without 
HCC.  In addition, 2,588 alcohol misusers, with no evidence of liver disease, were included to 
exclude the possibility that any observed genetic effect might relate to the susceptibility to 
develop problematic drinking. 
The results of the present study robustly establish that carriage of HSD17B13:rs72613567:TA 
protects against the development of alcohol-related cirrhosis and its subsequent evolution to 
HCC.  The results also confirm again that carriage of PNPLA3 rs738409 is associated with a 
significantly increased risk of developing alcohol-related cirrhosis and HCC.  However, the 
magnitude of these two effects is of a different order.  Thus, while carriage of the 
HSD17B13:rs72613567:TA allele reduces the PAF for cirrhosis by 14.7% and for HCC by 10%, 
carriage of the PNPLA3 rs738409:G allele increases the risks by 27.2% and 38.7% respectively.  
Thus, the combined PAF for cirrhosis was 16.5% and for HCC 32.5%.
Thus, the risk of carriage of PNPLA3 rs738409:G appears to be attenuated, to a degree, by co-
carriage of HSD17B13:rs72613567:TA.  Abul-Husn and colleagues20 explored the possibility of 
interactions between these two SNPs and observed nominally significant interactions in 
association analyses with serum transaminase activities, primarily in the obese, but not with 
chronic liver disease.  They also showed, using RNA sequencing–based expression analysis, that 
HSD17B13 rs72613567:TA was associated with decreased PNPLA3 messenger RNA expression in 
an allele dose-dependent manner.  However, exploration of SNP*SNP interaction, in the present 
study, showed no evidence of a significant interaction.  Yang and coworkers21 did not report data 
on possible SNP*SNP interaction so no further comparison can be made.
Male sex is a significant risk factor for the development of HCC in people with alcohol-related 
cirrhosis.12,13  The reasons for this are unknown.  Men are more likely to drink at harmful levels 
and hence more likely to develop alcohol-related cirrhosis but they are still proportionately over 
represented amongst those developing HCC.  Malignant transformation is more likely to occur in 
individuals with alcohol-related cirrhosis who stop drinking;30 hence the suggestion that the 
difference in sex-specific HCC rates may reflect lower abstinence rates amongst women.  The 
possibility of sex-genetic variant interactions should also be considered.  The comparative A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
survival advantage in women with alcohol-related cirrhosis is well-documented,31-33 and it has 
recently been shown that this may relate, at least in part, to a sex-variant interaction with 
rs738409:G in PNPLA3.34,35
The possibility of sex-variant interactions was also explored in the present study.  The progressive 
increase in the risk of developing alcohol-related cirrhosis and HCC associated with carriage of 
PNPLA3 rs738409:G HCC was observed in both men and women.  Likewise, the protective effect 
for cirrhosis risk associated with carriage of HSD17B13 rs72613567:TA was observed in both 
sexes.  However, the protective association of HSD17B13 rs72613567:TA and HCC was only found 
in men.  There was no significant sex difference in the MAFs for HSD17B13 rs72613567:TA in the 
alcohol misusers (26.3% vs. 26.6%) or in the patients with alcohol-related cirrhosis (22.4% vs. 
20.5%).  However, whereas the frequency further reduced in men with HCC (17.8%) the trend 
partially reversed in women (21.7%).  These findings are counterintuitive and are without 
explanation.  The number of women with HCC was relatively small so this finding needs further 
exploration in a larger cohort.  
Neither of the previous studies explored sex-differences in the effects of HSD17B13 
rs72613567:TA.20,21  However, Ferenci and colleagues,36 found sex-related phenotypic variation 
associated with carriage of HSD17B13 rs72613567:TA in patients with Wilson’s disease.  Thus, 
none of the in men who developed fulminant Wilson’s disease carried this HAS17B13 variant in 
contrast to 13.6% in their female counterparts.  Clearly, sex-gene variant interaction should be 
considered in any further genetic studies in the field of liver disease.
HSD17B13 belongs to the family of pluripotent 17-hydroxysteroid dehydrogenase enzymes 
whose members convert 17-keto- and 17-hydroxysteroids, regulate the biological activity of sex 
hormones, participate in fatty acid and cholesterol metabolism, and contribute to bile acid 
synthesis.37  The function of HSD17B13 is incompletely understood, but it is located on the 
surface of lipid droplets and is mainly expressed in the liver.  Su and colleagues38 have 
demonstrated that transcriptional regulation of HSD17B13 expression is likely to be liver X 
receptor (LXR)-mediated via a sterol-regulatory-element binding protein 1c (SREBP-1c)-
dependent mechanism; they also found evidence for a SREBP-1c response element (SRE) in the 
promoter region of the HSD17B13 gene located on chromosome 4q22.1.  HSD17B13 expression A
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is increased in patients with NAFLD39,40 and in murine models of fatty liver disease,41 and its 
overexpression in Huh-7 and HepG2 hepatoma cell lines results in accumulation of HSD17B13 on 
the surface of lipid droplets.40,42  
Ma and coworkers43 have recently shown that HSD17B13 is a hepatic retinol dehydrogenase.  
Retinal, retinoic acid and retinol binding protein have been implicated in the pathogenesis of 
steatosis, fibrosis, adipogenesis, and insulin resistance.44  Thus, HSD17B13 may be involved in the 
complex nuclear receptor interaction in NAFLD via activation of the retinoic acid receptor.45  Of 
greater importance, in the context of the present study, is the possibility that HSD17B13, 
functioning as a retinol dehydrogenase, may contribute to the depletion of hepatic retinoic acid 
observed in individuals chronically misusing alcohol.  Retinoic acid depletion results in a 
functional down regulation of liver retinoic acid receptors and a marked increase in the 
expression of the activator protein-1 (c-jun and c-fos) transcriptional complex which is associated 
with hepatic cell hyperproliferation, a decrease in apoptosis and stimulated hepatic 
carcinogenesis.46,47  The retinol dehydrogenase activity of the rs72613567:TA variant is likely 
reduced or absent and this may explain, at least in part, its protective effect against HCC in the 
context of alcohol-related cirrhosis.  Accordingly, repletion of hepatic retinoic acid 
concentrations experimentally or in patients with HCC may have a therapeutic role.48
There are some contrary findings in relation to the protective effect of a reduction in HSD17B13 
activity.  Chen and colleagues,49 for example, reported that mRNA expression of HSD17B13 was 
down regulated in Asians with hepatitis B (HBV)-related HCC, though not in HBV-related cirrhosis, 
and showed that low HSD17B13 expression in peritumour tissue was independently associated 
with a reduction in recurrence-free survival.  They also showed that overexpression of HSD17B13 
in Huh-7 cell and SK-HEP-1 cell lines results in delays in cell cycle progression.  Their overall 
conclusion, based on these findings, was that increased HSD17B13 expression might inhibit the 
development and progression of HBV-related HCC.  This contrast with the findings in the present 
study and those of others,20,21 that in Europeans, decreased expression of HSD17B13 protects 
against the development of both alcohol-related cirrhosis and its evolution to HCC.  This 
apparent contradiction may attest to differences in the mechanisms of HCC development in viral- 
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and alcohol-related liver disease.  Clearly further research on the functional role of HSD17B13 in 
HCC development and progression is needed.
There is considerable interest in the possibility of pharmaceutical inhibition of HSD17B13 to 
counteract the steatogenic effect of over expressed HSD17B13, and mimic the loss-of-function 
derived from the HSD17B13 rs72613567:TA variant.  For example, fenofibrate which is an agonist 
of the peroxisome proliferator-activated receptor- (PPAR) and approved for use in humans, 
suppresses hepatic HSD17B13 expression in mouse liver,50 a finding supported by the high 
expression of HSD17B13 observed in ppar knock-out mice.42  
This study has a number of strengths.  The study cohorts were large and well-characterized and 
specifically selected to explore the genetic risks associated with the development of alcohol-
related cirrhosis and HCC in Caucasians of European origin.  Controls were exercised for a 
number of known risk factors such as age, sex, BMI and diabetes.  Similar effect sizes were 
observed across all individual geographical cohorts excluding the possibility of heterogeneity 
and, thus, broadening the applicability of the findings.  The specificity of the genetic associations 
was explored by including a large control cohort of alcohol misusers who had no evidence of liver 
disease.
This study also has some limitations; first, it was cross-sectional and undertaken retrospectively, 
meaning that phenotypic data sets were not always complete.  Second, it is likely that some of 
the patients with alcohol-related cirrhosis will develop HCC over time and equally likely that 
some of the individuals misusing alcohol will develop cirrhosis in the future, particularly if they 
continue to drink.  However, the group differences were significant and remained robust to 
adjustment for confounders, including age.  Finally, the findings can not be used to define the 
genetic risks associated with the development of cirrhosis and HCC in people with liver disease of 
different aetiologies or from outside of Europe, as pointed out in relation to the findings of Chen 
and colleagues.49 
In conclusion: HSD17B13 rs72613567:TA protects against the development of alcohol-related 
cirrhosis and, at least in men, the subsequent development of HCC.  Its carriage attenuates the 
increased risk associated with carriage of PNPLA3 rs738409:G.  Combining phenotypic and 
genetic signatures to score risk could facilitate management of patients with alcohol-related liver A
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disease.  Further evaluation of the function of HSD17B13 and the rs72613567 variant may 
identify suitable drug targets.
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Legends to figures
Figure 1
Forrest plot showing genotypic ORs for heterozygous and homozygous carriage of the HSD17B13 
rs72613567:TA allele. Figure 1A: the unadjusted analysis; Figure 1B analysis adjusted for age, sex, 
body mass index (BMI), type 2 diabetes mellitus (T2DM) and country.  Homozygous carriage of 
HSD17B13 rs72613567:T wild type is set as a reference.
Figure 2
A: Relative proportions of patients with alcohol-related cirrhosis (CIRR) according to gene 
signature comprised of HSD17B13 rs72613567 and PNPLA3 rs739409 genotypes in relation to 
alcohol misusers without liver disease (ALC). 
B: Relative proportions of patients with HCC according to gene signature comprised of HSD17B13 
rs72613567 and PNPLA3 rs739409 genotypes in relation to patients with alcohol-related cirrhosis 
(CIRR). 
C: Proportions of HCC patients according to gene signature comprised of HSD17B13 rs72613567 
and PNPLA3 rs739409 genotypes in relation to alcohol misusers with no liver disease (ALC). 
Figure 3
A: Test for trend on the proportion of HSD17B13 rs72613567 genotypes in the three cohorts 
showing a gradual decrease in TA allele carriage with escalating severity of liver disease.
B: Test for trend on the proportion of HSD17B13 rs72613567 genotypes in women showing a 
decrease in TA carriage in patients with cirrhosis but not in patients with HCC.
C: Test for trend on the proportion of HSD17B13 rs72613567 genotypes in men showing a 
gradual decrease of TA allele carriage with escalating severity of liver disease.
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Table 1: Demographic characteristics of the study cohorts 
 
Cohorts Number Age [SD] Men (%) BMI [SD] T2DM Nicotine (% users) 
Alcohol-related cirrhosis with HCC  (HCC) 1031 62 [10]* 91* 27.8 [4.8] * 45%* 47%* 
Germany 778 61 [10] 91 27.8 [4.8] 45% 50% 
Switzerland 115 61 [11] 85 27.9 [5.0] 53% 38% 
United Kingdom 65 65 [9] 93 25.6 [3.1] 0% N/A 
Italy 73 72 [8] 92 N/A 47% 29% 
Alcohol-related cirrhosis without HCC (CIRR) 1653 55 [10] 
†
 72
†
 25.9 [4.9]
†
 16%
†
 61%
†
 
Germany 1050 56 [10] 72 26.2 [5.2] 22% 61% 
Switzerland 192 56 [10] 73 26.2 [5.8] 29% 48% 
United Kingdom* 376 53 [11] 68 24.6 [2.6] N/A N/A 
Italy 35 54 [9] 86 N/A 24% 66% 
Alcohol misusers (ALC) 2588 48 [10] 84 24.7 [4.1] 4% 79% 
Germany 1827 48 [9] 88 24.8 [4.3] 4% 81% 
Switzerland 417 45 [12] 74 24.4 [4.0] 14% 59% 
United Kingdom 344 49 [10] 76 24.7 [2.3] 2% N/A 
Italy N/A N/A N/A N/A N/A N/A 
BMI, body mass index; T2DM, type II diabetes mellitus; N/A, not available;  
 People with a BMI> 30 and/or with type II diabetes were excluded a priori;  A
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Significance of the difference between patients with alcohol-related cirrhosis with and without HCC: *p <0.001; 
Significance of the difference between patients with alcohol-related cirrhosis and alcohol misusers: 
†
p <0.001 
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Table 2: Univariate and multivariate analyses for association of HSD17B13 rs72613567 with alcohol-related cirrhosis and HCC in the total 
European cohort 
 
Cohorts HSD17B13 
(rs72613567) 
Comparative 
groups 
Genotypic 
OR (95% CI) 
regression model: A 
Genotypic 
OR (95% CI) 
regression model: B 
Regression 
model  
 
Allelic OR  
(95% CI) 
Significance 
(P) 
Cases/ 
controls 
(n) 
  HCC CIRR       
Alcoholic-
related cirrhosis 
and HCC  
(HCC) 
T|T 705 1027       
T|TA 287 524 0.80 (0.67-0.95) 0.92 (0.69-1.22) A 0.77 (0.68-0.89) 2.27×10-4 1031/1653 
TA|TA 39 102 0.56 (0.38-0.82) 0.43 (0.23-0.80) B 0.79 (0.63-0.99) 0.037 604/679 
MAF 0.177 0.220 P = 1.05×10-3 P = 0.028     
 
  CIRR ALC       
Alcohol-related 
cirrhosis 
without HCC  
(CIRR) 
T|T 1027 1401       
T|TA 524 1009 0.71 (0.62-0.81) 0.79 (0.63-0.98) A 0.79 (0.72-0.88) 8.13×10-6 1653/2588 
TA|TA 102 178 0.78 (0.61-1.01) 0.82 (0.54-1.23) B 0.85 (0.72-0.99) 0.048 679/1483 
MAF 0.220 0.264 P = 1.54×10-6 P = 0.085     
 
  HCC ALC       
Alcohol T|T 705 1401       A
cc
ep
te
d 
A
rt
ic
le
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misusers 
(ALC) 
T|TA 287 1009 0.57 (0.48-0.66) 0.68 (0.52-0.89) A 0.60 (0.53-0.69) 1.69×10-14 1031/2588 
TA|TA 39 178 0.44 (0.30-0.62) 0.39 (0.21-0.72) B 0.66 (0.53-0.81) 1.14×10-4 604/1483 
MAF 0.177 0.264 P = 3.32×10-14 P = 6.00×10-4     
 
 
CI, confidence intervals; MAF, minor allele frequency; OR, odds ratio  
Genotypic and allelic odds ratios were assessed by logistic regression models: model A - univariate logistic regression; model B –multivariate 
logistic regression adjusted for age, sex, body mass index, type 2 diabetes mellitus and country.  
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Table 3: Univariate and multivariate analyses for association of PNPLA3 rs738409 with alcohol-related cirrhosis and HCC in the total European 
cohort 
 
Cohorts 
PNPLA3  
(rs738409) 
Comparative 
groups 
Genotypic 
OR (95% CI) 
regression model: A 
Genotypic 
OR (95% CI) 
regression model: B 
Regression 
model  
 
Allelic OR  
(95% CI) 
Significance 
(P) 
Cases/ 
controls 
(n) 
Alcohol-related 
cirrhosis with HCC  
(HCC) 
 HCC CIRR       
C|C 269 697       
C|G 497 714 1.80 (1.50-2.16) 1.75 (1.30-2.36) A 1.77 (1.58-1.98) 2.31×10-23 1030/1631 
G|G 264 220 3.11 (2.48-3.90) 2.75 (1.88-4.01) B 1.67 (1.39-2.01) 7.19×10-8 603/660 
MAF 0.498 0.354 P = 2.98×10-22 P = 4.37×10-7     
 
Alcohol-related 
cirrhosis without 
HCC  
(CIRR) 
 CIRR ALC       
C|C 697 1364       
C|G 714 802 1.74 (1.52-2.00) 1.64 (1.31-2.06) A 1.70 (1.54-1.88) 1.52×10-26 1631/2319 
G|G 220 153 2.81 (2.25-3.53) 2.65 (1.85-3.78) B 1.63 (1.39-1.91) 1.67×10-9 660/1469 
MAF 0.354 0.239 P = 1.61×10-25 P = 1.31×10-8     
 
Alcohol misuse 
(ALC) 
 HCC ALC       
C|C 269 1364       A
cc
ep
te
d 
A
rt
ic
le
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C|G 497 802 3.14 (2.65-3.73) 2.75 (2.06-3.66) A 3.00 (2.67-3.36) 2.17×10-79 1030/2319 
G|G 264 153 8.75 (6.90-11.10) 6.76 (4.60-9.95) B 2.63 (2.18-3.17) 3.89×10-24 603/1469 
MAF 0.498 0.239 P = 4.14×10-78 P = 5.50×10-23     
 
 
CI, confidence intervals; MAF, minor allele frequency; OR, odds ratio 
Genotypic and allelic odds ratios were assessed by logistic regression models: model A - univariate logistic regression; model B –multivariate 
logistic regression adjusted for age, sex, body mass index, type 2 diabetes mellitus and country 
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